CYRAMZA

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK.

Active ingredients

The drug CYRAMZA contains one active pharmaceutical ingredient (API):

1	Ramucirumab UNII D99YVK4L0X - RAMUCIRUMAB
	Ramucirumab is a human receptor-targeted antibody that specifically binds VEGF Receptor 2 and blocks binding of VEGF-A, VEGF-C, and VEGF-D. Vascular Endothelial Growth Factor (VEGF) Receptor 2 is the key mediator of VEGF induced angiogenesis. As a result, ramucirumab inhibits ligand stimulated activation of VEGF Receptor 2 and its downstream signalling components, including p44/p42 mitogen-activated protein kinases, neutralising ligand-induced proliferation and migration of human endothelial cells.
	Read more about Ramucirumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CYRAMZA Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FG02	Ramucirumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FG VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors
Discover more medicines within L01FG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	507616050019702, 507616050019802
CA	Health Products and Food Branch	02443805
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	53-MBE-0416
EE	Ravimiamet	1674301, 1674312, 1674323
ES	Centro de información online de medicamentos de la AEMPS	114957001, 114957001IP, 114957003, 114957003IP
FI	Lääkealan turvallisuus- ja kehittämiskeskus	180634, 575246
FR	Base de données publique des médicaments	63848228
GB	Medicines & Healthcare Products Regulatory Agency	284694, 287914, 383722, 392347
HK	Department of Health Drug Office	64421, 64422
IL	מִשְׂרַד הַבְּרִיאוּת	7805, 7806
JP	医薬品医療機器総合機構	4291429A1023, 4291429A2020
LT	Valstybinė vaistų kontrolės tarnyba	1075373, 1075374, 1075375
NL	Z-Index G-Standaard, PRK	122777, 122785
NZ	Medicines and Medical Devices Safety Authority	18076, 18077
PL	Rejestru Produktów Leczniczych	100335298
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W61463001
SG	Health Sciences Authority	15035P, 15036P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699673765143, 8699673765150, 8699673765167
US	FDA, National Drug Code	0002-7669, 0002-7678